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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: To evaluate the effectiveness and safety of high-power 120W Green-
light HPS laser (HPS) and compare the results to transurethral resection of the prostate
(TURP), and define a subgroup of patients who had better symptom score improvement after
HPS.
Methods: One hundred and twenty-five patients who underwent surgery for benign prostatic
hyperplasia (BPH) (61 HPS and 64 TURP) were retrospectively followed. Improvements of
International Prostate Symptom Score (IPSS), quality of life score (QoL), maximum flow rate
(Qmax) and post-void residual (PVR) were assessed at 4 weeks after the procedures.
Potential covariates including age, body mass index (BMI), prostate volume (PV) and
serum prostate-specific antigen (PSA) were defined and further subgroup analyses were
utilized.
Results: The HPS group had a significantly higher education level, annual household income
and larger prostate size. Compared with TURP, HPS resulted in comparable IPSS, QoL, Qmax
and PVR improvements, but shorter hospitalization duration, serum hemoglobin loss and
blood transfusion rate. Subgroup analyses showed that men in the HPS group were younger
(age< 76 years), had higher BMI (24 kg/m2) and greater adjusted IPSS and QoL improve-
ments than men in the TURP group.Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
w (K.-L. Chien).
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BMI and age predict laser outcomes for BPH 269Conclusion: HPS offered adequate effectiveness for symptomatic BPH versus TURP and was
advantageous with regard to operative safety. Patients who are younger and have higher
BMI may achieve better improvements with HPS than with TURP. Further long-term follow-
up study is warranted.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Transurethral resection of the prostate (TURP) has been the
most commonly used procedure for benign prostatic
hyperplasia (BPH) with apparently subjective and objective
improvements,1 but the associated bleeding and high
complication rates restrict the applications to a selected
population.2,3
The photoselective vaporization (PVP) with potassium-
titanyl-phosphate (KTP) laser was established as a useful
and safe alternative for symptomatic BPH.4e7 The more
powerful 120W Greenlight HPS laser (HPS) was developed
recently to utilize a higher rate of energy and improve
efficacy,8e10 but the evidence for which subgroup will
benefit more from HPS is scarce.11
In this study, we assessed the outcomes of men with
symptomatic BPH after utilization of the HPS, compared
the results to TURP, and defined a potential subgroup of
patients that would have more symptom score improve-
ment after HPS.Materials and methods
Participants
From January 2007 to December 2009, 125 men with
symptomatic BPH who underwent either HPS or TURP were
retrospectively followed. The protocol was approved by the
hospital ethics committee and informed consent was ob-
tained from all patients. Inclusion criteria for the study
were International Prostate Symptom Score (IPSS) greater
than 7, Qmax less than 15 mL/s or acute urinary retention.
Patients who had prostate cancer, prior prostatic or urethral
surgery, or bladder tumor were excluded from the study.
Men taking anticoagulants maintained medication before
and after HPS during hospitalization, while TURP patients
stopped taking the drugs for at least 1 week. There were 61
men enrolled in the HPS group and 64 in the TURP group.
Most procedures were performed under spinal anesthesia.
Basic data such as age, height and weight were
collected. The education level of the patients and annual
household income were recorded by special nurses at
admission. Validated IPSS and quality of life score (QoL)
questionnaires were completed. Uroflowmetry was per-
formed and baseline maximum flow rate (Qmax) and post-
void residual urine (PVR) were also evaluated. Biochemical
assessments were done as follows: urine analysis, serum
sodium, hemoglobin and prostate-specific antigen (PSA)
level. Prostate volume (PV) was evaluated using transrectal
ultrasound (TRUS) measurement. The American Society of
Anesthesiologists (ASA) score for each patient wascalculated by an experienced anesthesiologist. High oper-
ation risk was defined as patients with an ASA score greater
than 2 and/or taking anticoagulants or with a bleeding
tendency. In patients with elevated PSA level or abnormal
digital rectal examination TRUS-guided biopsies were
performed.
Standard TURP was performed by using the 26F
continuous-flow monopolar resectoscope. A 22F three-way
Foley urethral catheter was left in place postoperatively.
HPS was performed with a 120W (The Greenlight HPS) laser
generator with the laser energy delivered by a side-firing
fiber through a 24F continuous-flow cystoscope. The energy
was absorbed by hemoglobin in the prostate tissue, and it
vaporized the prostate tissue and ended with a wide-
opened TURP-like cavity.
Serum sodium and hemoglobin level were collected
again within 4 hours postoperation. Hospitalization dura-
tion was defined as between the time between admission
day (1 day before operation) and the discharge day and was
recorded by a special nurse. Four functional outcomes
including IPSS, QoL, Qmax and PVR improvements were
evaluated 4 weeks later in urology clinics.
Statistics
Continuous variables were analyzed with the Student t test
and are presented as mean standard deviation (SD).
Categorical variables were analyzed with the Chi-square
test and are recorded as frequency or percentage. The
two-sided alpha level was 0.05. A p value of less than 0.05
was considered to be statistically significant. A general
linear model was used for detailed clinical covariate
adjustments and four covariates including age, BMI, PV, and
PSA were presented for subgroup analysis, with the median
value as the cut-off point for each group. All statistical
calculation was performed using SAS Version 9.1 (SAS Insti-
tute, Cary, NC) and STATA Version 10.0 (Stata Corporation,
College Station, Texas) was used for figures of box plots.
As for sample size determination, according to previous
studies, IPSS improvement greater than 4.9 was considered
significantly different.12 We set IPSS improvement as 5,
within group standard deviation as 7, alpha level 0.05 and
power value of 0.8, and the estimated sample size as 43 in
each group.Results
The baseline characteristics for both groups are listed in
Table 1. Compared with the TURP group, HPS patients had
a significantly higher education level, household income
and larger prostate size. Twenty-one HPS patients (34%)
Table 1 Preoperative demographics for patients receiving treatment with 120W Greenlight HPS laser (HPS) or transurethral
resection of the prostate (TURP).
HPS TURP p
nZ 61 nZ 64
Age (y) 74.1 9.76 (50e99) 76.1 7.74 (55e89) 0.21
Height (cm) 166 6.31 (140e180) 164 6.87 (150e178) 0.17
Weight (kg) 65.9 9.60 (44e89) 62.4 10.6 (40e83) 0.06
Body mass index (kg/m2) 24.0 3.09 (16.2e30.8) 23.3 3.55 (15.2e31.3) 0.26
Prostate volume (g) 60.9 26.1 (25e136) 51.6 23.4 (20e101) 0.04
Prostate-specific antigen (ng/mL) 7.48 10.4 (0.4e29.1) 6.81 5.12 (0.3e19.8) 0.70
IPSS 19.5 6.32 (11e35) 21.4 7.00 (8e35) 0.14
Postvoided residual (mL) 208 200 (0e800) 190 217 (35e950) 0.64
Maximum uroflow (mL/second) 9.86 3.45 (2.5e13.5) 9.41 3.64 (1.5e13.5) 0.56
Quality of life score 4.61 0.77 (2e6) 4.48 1.01 (2e6) 0.44
Anesthesia score 2.14 0.59 (1e3) 2.29 0.61 (1e3) 0.20
Socioeconomic status
Education (%) 0.002
Elementary school or less 32 53
High school 27 27
College 41 20
Household incomea 0.01
Low 24 6
Averaged 16 8
High 60 86
Numeric data are expressed as means SD and compared with the t test. Categorical data are expressed as numbers (percentage) and
compared with the Chi-square test.
IPSSZ International Prostate Symptom Score.
a Low household income means an annual income less than 0.6 million NT dollars; averaged is between 0.6 and 1 million NT dollars;
high is more than 1 million NT dollars.
Table 2 The major operative outcomes for the enrolled
patients (nZ 125) receiving treatment with 120W Green-
light HPS laser (HPS) or transurethral resection of the
prostate (TURP).
HPS TURP p
nZ 61 nZ 64
IPSS decrease 13.5 5.00 12.2 4.60 0.15
Quality of life score
decrease
2.91 0.91 2.60 0.99 0.09
Postvoided residual
change (mL)
169 189 138 185 0.39
Maximum uroflow
change (mL/second)
7.58 6.39 7.12 4.49 0.71
Hospitalization
duration (d)
3.54 1.99 5.74 1.84 <0.0001
Operation time (min) 148 53.5 81.0 29.5 <0.0001
Serum hemoglobin
change (g/L)
0.80 0.68 1.10 0.69 0.002
Serum sodium change
(mmol/L)
0.98 1.56 1.99 1.62 0.031
Numeric data are expressed as means SD and compared with
the t test. Categorical data are expressed as numbers
(percentage) and compared with the Chi-square test.
IPSSZ International Prostate Symptom Score.
270 T.-K. Yang et al.had high operation risk including 13 with ASA scores of 3 and
8 who were on anticoagulant therapy, lower than TURP
patients (39%, pZ 0.41). Table 2 lists the major preoper-
ative and operative outcomes. The HPS group had compa-
rable results in four functional parameters versus TURP, and
had significantly shorter hospitalization duration, less
serum sodium and hemoglobin decrease, but longer oper-
ative time.
Fig. 1 shows the box plots of the adjusted IPSS
improvement for the defined subgroup. In the subgroup of
patients with younger age (age< 76 years), after adjust-
ment for baseline IPSS, BMI, baseline prostate volume,
education level and household income, the IPSS decrease
for HPS and TURP was 14.9 and 11.8 (pZ 0.04), respec-
tively; and in the older subgroup it was 12.6 for HPS and
11.5 for TURP (pZ 0.13). Men with higher BMI had better
adjusted IPSS improvement after HPS (15.3 vs. 12.2,
pZ 0.01). Within the HPS group, younger patients had
significantly greater adjusted IPSS improvement (15.5 vs.
12.4, pZ 0.007; figure not shown).
The box plots of the adjusted QoL are presented in
Fig. 2. Patients who were younger and had higher BMI had
better QoL improvements after HPS versus TURP (pZ 0.04
and 0.01, respectively).
Discussion
Our results showed comparable functional outcomes
including IPSS, QoL Qmax and PVR improvements between
Figure 1 Box plots of the International Prostate Symptom Score (IPSS) improvements for the four patient subgroups, adjusted for
baseline IPSS, age, body mass index (BMI), prostatic volume, educational level and annual income. Treatment with 120W Greenlight
HPS laser (HPS) is compared with transurethral resection of the prostate (TURP).
BMI and age predict laser outcomes for BPH 271HPS and TURP. IPSS decreased 70% (13.5 points) from
baseline for the HPS group, which is similar to that re-
ported in many published series.6,13e15 Compared to TURP,
HPS accounts for lower hemoglobin and electrolyte lossFigure 2 Box plots of the quality of life (QoL) improvements for t
mass index (BMI), prostatic volume, educational level and annua
compared with transurethral resection of the prostate (TURP).and adequate safety. Surgeons may recommend HPS for
large prostate patients who can afford the cost of the
procedure, especially men with a high-risk or moderate-
to-severe condition with comorbidity. In the presenthe four patient subgroups, adjusted for baseline QoL, age, body
l income. Treatment with 120W Greenlight HPS laser (HPS) is
272 T.-K. Yang et al.study, the HPS patients had significantly larger prostates,
which may resulted in more adenoma volume reduction
and insignificantly better IPSS and QoL improvements than
TURP.
Because of the bloodless nature of the procedure and
the use of saline irrigation during the HPS, surgeons have
a clear operation field most of the time, even after a 3-hour
surgery. No obvious bleeding or blood loss was noted in HPS
men taking anticoagulants. Most operations were done by
one experienced surgeon who had performed similar laser
surgery in more than 20 cases for HPS, so the learning curve
effects of the technique were minimized.16,17
We used several potential confounders, including age,
BMI, baseline prostate volume, educational level and
annual income as covariates for IPSS and QoL adjustment in
subgroup analyses. The results showed that younger age
and higher BMI will achieve better adjusted IPSS and QoL
improvements after HPS, and TURP affords the smallest
symptom score improvements in men with older age and
lower BMI. Similar results were noted in recent reports of
the CombAT study, which document more IPSS improve-
ments in men who are younger and have higher BMI after
prostate volume reduction therapy.18
The International Greenlight User (IGLU) study resulted
in greater volume reduction in patients with larger prostate
volume, but no IPSS decrease difference.19 A previous study
stated that TURP is superior to KTP laser in patients with
larger prostates, although the latter has advantages with
regard to intraoperative and perioperative safety.11 Our
results showed there is no IPSS and QoL decrease difference
between the two procedures for larger and smaller PV
groups.
Because laser therapy for symptomatic BPH is a rela-
tively expensive procedure in Taiwan, it is important to
predict which subgroups of patients are most likely to
benefit from HPS so that unsuitable patients can be
directed to alternative procedures. According to our
results, primary physicians can make predictions according
to BMI and age with ease and better suggestions can be
given properly before referral.
One of the major limitations of this study is that the cost
of laser therapy for symptomatic BPH is not covered by
national insurance in Taiwan, so patients who cannot afford
the procedure might be excluded from the HPS group, which
may bias the results. However, we think the basic demo-
graphics of our patients truly reflect the current medical
circumstance in Taiwan. Another limitation was lack of
adenoma volume reduction and energy utilization data,
which may provide more information to support the results.
A randomized, double-blind, and placebo-controlled study
in a larger sample size is warranted to clarify the effect of
HPS and the patient subgroups that will benefit most from it.
The limitations of HPS in this study were the long
operative time and high recatheterization rate (8.2% vs.
4.7% in TURP, data not shown). The vaporization-only
technique requires more time, energy and laser fibers
during the procedure,20 especially in the first few cases.
The depth of necrotic tissue (coagulation zone) after the
vaporization-only technique in the present study may be
larger than others such as the enucleation technique21 and
causes more temporary urinary retention rates after the
Foley catheter is removed. We think that modernmodified techniques such as vaporizationeresection or
enucleation methods9,20,22 will improve these drawbacks in
the future.
Conclusion
HPS offers adequate efficacy for BPH versus TURP and is
advantageous with regards to operative safety. Younger
patients (age< 76 years) and those with higher BMI
(BMI 24) may achieve better symptom scores, and both
IPSS and QoL improvements after HPS. Long-term follow-up
is needed to evaluate the durability and possible morbidity
for HPS.
Acknowledgments
Author contributions: TK Yang had full access to all the data
in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis. Study concept
and design: TK Yang, Hsiao, Chien. Acquisition of data: TK
Yang. Analysis and interpretation of data: TK Yang, HJ
Yang, Chien. Drafting of the manuscript: TK Yang. Critical
revision of the manuscript for important intellectual
content: Hsiao, TK Yang, HJ Yang, Liao, Chiang, Chien.
Statistical analysis: TK Yang, HJ Yang. Obtaining funding:
none. Administrative, technical, or material support: TK
Yang, HJ Yang, Hsiao. Supervision: Chien.
References
1. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM,
Henderson WG. A comparison of transurethral surgery with
watchful waiting for moderate symptoms of benign prostatic
hyperplasia. The Veterans Affairs Cooperative Study Group on
Transurethral Resection of the Prostate. N Engl J Med 1995;
332:75e9.
2. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transure-
thral prostatectomy: immediate and postoperative complica-
tions. A cooperative study of 13 participating institutions
evaluating 3885 patients. J Urol 1989;141:243e7.
3. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of
transurethral resection of the prostate (TURP) e incidence,
management, and prevention. Eur Urol 2006;50:969e79.
discussion 980.
4. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA,
et al. Photoselective vaporization of the prostate for the
treatment of benign prostatic hyperplasia: 12-month results
from the first United States multicenter prospective trial. J
Urol 2004;172:1404e8.
5. Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, et al.
GreenLight laser vaporization of the prostate: single-center
experience and long-term results after 500 procedures. Eur
Urol 2008;54:893e901.
6. Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P,
Costello AJ. KTP laser versus transurethral resection: early
results of a randomized trial. J Endourol 2006;20:580e5.
7. Heinrich E, Schiefelbein F, Schoen G. Technique and short-term
outcome of green light laser (KTP, 80W) vaporisation of the
prostate. Eur Urol 2007;52:1632e7.
8. Capitan C, Blazquez C, Martin MD, Hernandez V, de la Pena E,
Llorente C. GreenLight HPS 120-W laser vaporization versus
transurethral resection of the prostate for the treatment of
lower urinary tract symptoms due to benign prostatic
BMI and age predict laser outcomes for BPH 273hyperplasia. A randomized clinical trial with 2-year follow-up.
Eur Urol 2011.
9. Brunken C, Seitz C, Tauber S, Schmidt R. Transurethral
GreenLight laser enucleation of the prostate. A feasibility
study. J Endourol 2011;25:1199e201.
10. Chiang PH, Chen CH, Kang CH, Chuang YC. GreenLight HPS
laser 120-W versus diode laser 200-W vaporization of the
prostate: comparative clinical experience. Lasers Surg Med
2010;42:624e9.
11. Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C.
Photoselective potassium titanyl phosphate (KTP) laser
vaporization versus transurethral resection of the prostate for
prostates larger than 70 mL: a short-term prospective
randomized trial. Urol 2008;71:247e51.
12. Barry MJ, Girman CJ, O’Leary MP, Walker-Corkery ES,
Binkowitz BS, Cockett AT, et al. Using repeated measures of
symptom score, uroflowmetry and prostate specific antigen in
the clinical management of prostate disease. Benign Prostatic
Hyperplasia Treatment Outcomes Study Group. J Urol 1995;
153:99e103.
13. Wendt-Nordahl G, Bucher B, Hacker A, Knoll T, Alken P,
Michel MS. Improvement in mortality and morbidity in tran-
surethral resection of the prostate over 17 years in a single
center. J Endourol 2007;21:1081e7.
14. Rajbabu K, Chandrasekara SK, Barber NJ, Walsh K, Muir GH.
Photoselective vaporization of the prostate with the
potassium-titanyl-phosphate laser in men with prostates of
>100 mL. BJU Int 2007;100:593e8. discussion 598.
15. Al-Ansari A, Younes N, Sampige VP, Al-Rumaihi K, Ghafouri A,
Gul T, et al. GreenLight HPS 120-W laser vaporization versus
transurethral resection of the prostate for treatment of benignprostatic hyperplasia: a randomized clinical trial with midterm
follow-up. Eur Urol 2010;58:349e55.
16. de la Rosette J, Alivizatos G. Lasers for the treatment of
bladder outlet obstruction: are they challenging conventional
treatment modalities? Eur Urol 2006;50:418e20.
17. Rajbabu K, Muir GH. GreenLight photoselective vaporization of
prostate e a technical review. Prostate Cancer Prostatic Dis
2007;10:s6e8.
18. Roehrborn CG, Siami P, Barkin J, Damiao R, Becher E, Minana B,
et al. The influence of baseline parameters on changes in
international prostate symptom score with dutasteride, tam-
sulosin, and combination therapy among men with symptom-
atic benign prostatic hyperplasia and an enlarged prostate: 2-
year data from the CombAT study. Eur Urol 2009;55:461e71.
19. Woo H, Oliver R, Bachmann A, Chao B, Collins E, De la
Rosette J, et al. Outcome of GreenLight HPS 120-W laser
therapy in specific patient populations: those in retention, on
anticoagulants, and with large prostates (80 ml). Eur Urol
2008;7:378e83.
20. Son H, Ro YK, Min SH, Choo MS, Kim JK, Lee CJ. Modified
vaporization-resection for photoselective vaporization of the
prostate using a GreenLight high-performance system 120-W
laser: the Seoul technique. Urol 2011;77:427e32.
21. Naspro R, Bachmann A, Gilling P, Kuntz R, Madersbacher S,
Montorsi F, et al. A review of the recent evidence (2006e2008)
for 532-nm photoselective laser vaporisation and holmium
laser enucleation of the prostate. Eur Urol 2009;55:1345e57.
22. Szlauer R, Gotschl R, Razmaria A, Paras L, Schmeller NT.
Endoscopic vaporesection of the prostate using the continuous-
wave 2-microm thulium laser: outcome and demonstration of
the surgical technique. Eur Urol 2009;55:368e75.
